Effect of pretreatment with omalizumab on the tolerability of specific immunotherapy in allergic asthma.

[1]  U. Wahn,et al.  Safety of anti‐IgE treatment with omalizumab in children with seasonal allergic rhinitis undergoing specific immunotherapy simultaneously , 2010, Pediatric allergy and immunology : official publication of the European Society of Pediatric Allergy and Immunology.

[2]  Linda Cox,et al.  Advantages and disadvantages of accelerated immunotherapy schedules. , 2008, The Journal of allergy and clinical immunology.

[3]  Vicki Seyfert-Margolis,et al.  Omalizumab pretreatment decreases acute reactions after rush immunotherapy for ragweed-induced seasonal allergic rhinitis. , 2006, The Journal of allergy and clinical immunology.

[4]  T. Keil,et al.  The co‐seasonal application of anti‐IgE after preseasonal specific immunotherapy decreases ocular and nasal symptom scores and rescue medication use in grass pollen allergic children , 2004, Allergy.

[5]  M. Cowles.  Modelling Survival Data in Medical Research (2nd ed.) (Book) , 2004 .

[6]  G. Liss,et al.  Twelve-year survey of fatal reactions to allergen injections and skin testing: 1990-2001. , 2004, The Journal of allergy and clinical immunology.

[7]  T. Casale,et al.  Omalizumab treatment downregulates dendritic cell FcεRI expression , 2003 .

[8]  S. Dreskin,et al.  A double-blind, placebo-controlled immunotherapy dose-response study with standardized cat extract. , 2003, The Journal of allergy and clinical immunology.

[9]  T. Casale,et al.  Omalizumab treatment downregulates dendritic cell FcepsilonRI expression. , 2003, The Journal of allergy and clinical immunology.

[10]  K. Bergmann,et al.  Efficacy of combination treatment with anti-IgE plus specific immunotherapy in polysensitized children and adolescents with seasonal allergic rhinitis. , 2002, The Journal of allergy and clinical immunology.

[11]  R. Lockey.  "ARIA": global guidelines and new forms of allergen immunotherapy. , 2001, The Journal of allergy and clinical immunology.

[12]  W. Busse,et al.  Omalizumab, anti-IgE recombinant humanized monoclonal antibody, for the treatment of severe allergic asthma. , 2001, The Journal of allergy and clinical immunology.

[13]  R. Townley,et al.  The anti-IgE antibody omalizumab reduces exacerbations and steroid requirement in allergic asthmatics. , 2001, The European respiratory journal.

[14]  S. Durham,et al.  Grass pollen immunotherapy for seasonal rhinitis and asthma: a randomized, controlled trial. , 2001, The Journal of allergy and clinical immunology.

[15]  Gary G. Koch,et al.  Categorical data analysis using the sas® system, 2nd edition , 2000 .

[16]  John M. Lachin,et al.  Biostatistical Methods: The Assessment of Relative Risks , 2000 .

[17]  Adkinson Nf.  Immunotherapy for Allergic Rhinitis , 1999 .

[18]  A. Togias,et al.  Down-regulation of Fc(epsilon)RI expression on human basophils during in vivo treatment of atopic patients with anti-IgE antibody. , 1997, Journal of immunology.

[19]  R. Pauwels,et al.  GLOBAL STRATEGY FOR ASTHMA MANAGEMENT AND PREVENTION , 1996 .

[20]  H. Malling,et al.  Antihistamine premedication in specific cluster immunotherapy: a double-blind, placebo-controlled study. , 1996, The Journal of allergy and clinical immunology.

[21]  Gary G. Koch,et al.  Categorical Data Analysis Using The SAS1 System , 1995 .

[22]  David Collett.  Modelling Survival Data in Medical Research , 1994 .

[23]  L. Freedman.  Tables of the number of patients required in clinical trials using the logrank test. , 1982, Statistics in medicine.

[24]  H. L. Mueller,et al.  Diagnosis and treatment of insect sensitivity. , 1966, The Journal of asthma research.